Old Web
English
Sign In
Acemap
>
authorDetail
>
Thomas Kerbusch
Thomas Kerbusch
Pfizer
Population
Pharmacokinetics
Pharmacology
NONMEM
Darifenacin
5
Papers
117
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid
2016
British Journal of Clinical Pharmacology
J. G. Coen van Hasselt
Matthew L. Rizk
Mallika Lala
Cynthia Chavez-Eng
Sandra A.G. Visser
Thomas Kerbusch
Meindert Danhof
Gauri Rao
Piet H. van der Graaf
Show All
Source
Cite
Save
Citations (21)
Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug–drug interactions: using in vitro data as an aid to assess study power
2009
Pharmaceutical Statistics
Trevor N. Johnson
Thomas Kerbusch
Barry C. Jones
Geoffrey T. Tucker
Amin Rostami-Hodjegan
Peter A. Milligan
Show All
Source
Cite
Save
Citations (14)
Planning for an adaptive design: a case study in COPD
2006
Pharmaceutical Statistics
Byron Jones
G. Atkinson
J. Ward
E. Tan
Thomas Kerbusch
Show All
Source
Cite
Save
Citations (0)
Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability
2003
British Journal of Clinical Pharmacology
Thomas Kerbusch
Ulrika Wählby
Peter A. Milligan
Mats O Karlsson
Show All
Source
Cite
Save
Citations (52)
Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic–pharmacodynamic data
2003
British Journal of Clinical Pharmacology
Thomas Kerbusch
Peter A. Milligan
Mats O Karlsson
Show All
Source
Cite
Save
Citations (30)
1